{"nctId":"NCT00317642","briefTitle":"A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","startDateStruct":{"date":"2006-08"},"conditions":["Acute Myelogenous Leukemia"],"count":326,"armGroups":[{"label":"clofarabine (IV formulation) and cytarabine","type":"EXPERIMENTAL","interventionNames":["Drug: clofarabine (IV formulation)","Drug: cytarabine"]},{"label":"placebo and cytarabine","type":"EXPERIMENTAL","interventionNames":["Drug: placebo","Drug: cytarabine"]}],"interventions":[{"name":"clofarabine (IV formulation)","otherNames":["Clolar®","Evoltra®"]},{"name":"placebo","otherNames":[]},{"name":"cytarabine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of Acute Myelogenous Leukemia (AML) according to World Health Organization (WHO) classification\n* Relapsed after receiving up to 2 prior induction regimens (i.e. first or second relapse)or are refractory to not more than one prior combination chemotherapy induction regimen\n* Be ≥ 55 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2\n* Be able to comply with study procedures and follow-up examinations\n* Be nonfertile or agree to use birth control during the study through the end of treatment visit and for at least 90 days after the last dose of study drug\n* Have adequate liver and renal function as indicated by certain laboratory values\n\nExclusion Criteria:\n\n* Received previous treatment with clofarabine\n* Received bolus, intermediate or high-dose cytarabine as induction therapy unless certain remission criteria are met\n* Have received a hematopoietic stem cell transplant (HSCT) within the previous 3 months\n* Have moderate or severe graft versus host disease (GVHD), whether acute or chronic\n* Are receiving any other chemotherapy or investigational therapy. Patients must have been off prior AML therapy for at least 2-6 weeks prior to entering study.\n* Have a psychiatric disorder that would interfere with consent, study participation, or follow-up\n* Have an active, uncontrolled infection\n* Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system\n* Have been diagnosed with another malignancy, unless disease-free for at least 5 years; patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed; patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed.\n* Have clinical evidence suggestive of central nervous system (CNS) involvement with leukemia unless lumbar puncture confirms absence of leukemic blasts in the cerebrospinal fluid(CSF)\n* Known HIV positivity\n* Are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)","description":"Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"6.4","spread":null},{"groupId":"OG002","value":"5.1","spread":null},{"groupId":"OG003","value":"5.5","spread":null},{"groupId":"OG004","value":"8.7","spread":null},{"groupId":"OG005","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Response Per Independent Response Review Panel (IRRP) Assessment - Overall and by Calculated Strata (CSR 7-April-11)","description":"Percentage of participants whose best response was assessed by the IRRP as complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) using the revised International Working Group for Response Criteria (Cheson 2003).\n\nCR is defined on morphologic criteria at a single response assessment:\n\n* a bone marrow aspirate or biopsy of \\<5% blasts, with evidence of normal hematopoiesis;\n* absence of Auer rods in the blasts that are present;\n* absence of extramedullary disease;\n* absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;\n* only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;\n* recovery of peripheral counts (platelets ≥100\\*10\\^9/L and absolute neutrophil count (ANC) ≥1.0\\*10\\^9/L).\n\nCRi met all criteria for CR except for either residual neutropenia (ANC \\<1.0\\*10\\^9/L) or thrombocytopenia (platelet count \\<100\\*10\\^9/L).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"22.9","spread":null},{"groupId":"OG002","value":"45.5","spread":null},{"groupId":"OG003","value":"22.9","spread":null},{"groupId":"OG004","value":"48.6","spread":null},{"groupId":"OG005","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null},{"groupId":"OG001","value":"17.8","spread":null},{"groupId":"OG002","value":"33.0","spread":null},{"groupId":"OG003","value":"18.1","spread":null},{"groupId":"OG004","value":"37.8","spread":null},{"groupId":"OG005","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"12.5","spread":null},{"groupId":"OG003","value":"4.8","spread":null},{"groupId":"OG004","value":"10.8","spread":null},{"groupId":"OG005","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Remission (DOR) Per IRRP Assessment-Overall and by Calculated Strata (CSR 7-April-11)","description":"DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy \\[including hematopoietic stem cell transplant\\] while in remission, or death due to any cause, whichever occurred first.\n\nCR is defined on morphologic criteria at a single response assessment:\n\n* a bone marrow aspirate or biopsy of \\<5% blasts, with evidence of normal hematopoiesis;\n* absence of Auer rods in the blasts that are present;\n* absence of extramedullary disease;\n* absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;\n* only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;\n* recovery of peripheral counts (platelets ≥100\\*10\\^9/L and absolute neutrophil count (ANC) ≥1.0\\*10\\^9/L).\n\nCRi met all criteria for CR except for either residual neutropenia (ANC \\<1.0\\*10\\^9/L) or thrombocytopenia (platelet count \\<100\\*10\\^9/L).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"5.7","spread":null},{"groupId":"OG003","value":"6.3","spread":null},{"groupId":"OG004","value":"11.5","spread":null},{"groupId":"OG005","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Remission (DOR) Per IRRP Assessment-Overall and by Randomized Strata (CSR 9-July-12)","description":"DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy \\[including hematopoietic stem cell transplant\\] while in remission, or death due to any cause, whichever occurred first.\n\nCR is defined on morphologic criteria at a single response assessment:\n\n* a bone marrow aspirate or biopsy of \\<5% blasts, with evidence of normal hematopoiesis;\n* absence of Auer rods in the blasts that are present;\n* absence of extramedullary disease;\n* absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;\n* only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;\n* recovery of peripheral counts (platelets ≥100\\*10\\^9/L and absolute neutrophil count (ANC) ≥1.0\\*10\\^9/L).\n\nCRi met all criteria for CR except for either residual neutropenia (ANC \\<1.0\\*10\\^9/L) or thrombocytopenia (platelet count \\<100\\*10\\^9/L).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"6.7","spread":null},{"groupId":"OG003","value":"6.3","spread":null},{"groupId":"OG004","value":"10.2","spread":null},{"groupId":"OG005","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)","description":"Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.\n\nSee Outcome #3 for definition of CR and CRi.\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"5.7","spread":null},{"groupId":"OG003","value":"6.7","spread":null},{"groupId":"OG004","value":"10.3","spread":null},{"groupId":"OG005","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)","description":"Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.\n\nSee Outcome #3 for definition of CR and CRi.\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"6.7","spread":null},{"groupId":"OG003","value":"6.7","spread":null},{"groupId":"OG004","value":"15.4","spread":null},{"groupId":"OG005","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)","description":"Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.\n\nTreatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, \\<30% decrease in % leukemic blasts).\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.4","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null},{"groupId":"OG005","value":"1.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)","description":"Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 randomized strata. OS was defined as the number of months from date of randomization until date of death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"4.8","spread":null},{"groupId":"OG003","value":"6.3","spread":null},{"groupId":"OG004","value":"9.7","spread":null},{"groupId":"OG005","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)","description":"Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.\n\nTreatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, \\<30% decrease in % leukemic blasts).\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.1","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"2.8","spread":null},{"groupId":"OG005","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Four-Month Event-free Survival Per IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)","description":"Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.\n\nTreatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, \\<30% decrease in % leukemic blasts).\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"16.6","spread":null},{"groupId":"OG002","value":"35.2","spread":null},{"groupId":"OG003","value":"16.9","spread":null},{"groupId":"OG004","value":"40.5","spread":null},{"groupId":"OG005","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Four-Month Event-free Survival Per IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)","description":"Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.\n\nTreatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, \\<30% decrease in % leukemic blasts).\n\nDisease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"17.1","spread":null},{"groupId":"OG002","value":"31.4","spread":null},{"groupId":"OG003","value":"17.9","spread":null},{"groupId":"OG004","value":"47.4","spread":null},{"groupId":"OG005","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Adverse Events (CSR 7-April-11)","description":"Number of participants with treatment emergent adverse events (TEAEs) or death due to related AE. Related AEs for the combination arm can be related to either clofarabine or cytarabine.\n\nGrade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life Threatening AE, Grade 5 = Death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":97,"n":161},"commonTop":["Nausea","Diarrhoea","Oedema peripheral","Constipation","Vomiting"]}}}